BRISTOL MYERS SQUIBB

📅 Upcoming

🕒 Recent(90d)

News

• Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
  Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
  fiercebiotech · 8h ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 10h ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 3d ago
• In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
  In his first interview after taking the reins of the FDA’s Oncology Center of Excellence, Angelo de Claro, M.D., is outlining a regulatory agenda that prioritizes organizational strength and contin…
  fiercebiotech · 3d ago
• Chutes & Ladders—Longtime Takeda R&D chief to depart next June
  Takeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.
  fiercebiotech · 3d ago
• Tyra shares slip as bladder cancer responses fall short of investor expectations
  Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
  biospace · 4d ago
• Merck adds 53 to New Jersey chopping block
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 4d ago
• BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
  Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, accordin…
  biospace · 5d ago
• Beeline Medicines reports promising Phase 2 lupus data
  The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb. The buzzy Bain-backed startup sai…
  endpoints · 5d ago
• A new immuno-oncology play raises $225M for a next-generation drug
  Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
  biopharma_dive · 5d ago